NIKKEI 225
38,835.10 +599.03 (+1.57%) HANG SENG
18,479.37 -98.93 (-0.53%) CRUDE OIL
78.84 +0.36 (+0.46%) GOLD FUTURES
2,323.40 -7.80 (-0.33%) DOW
38,894.45 +42.18 (+0.11%) Bitcoin GBP
50,722.01 +77.63 (+0.15%)
Gilead Sciences, Inc. (GIS.DE)
| Previous close | 59.79 |
| Open | 60.67 |
| Bid | 61.25 x 25500 |
| Ask | 61.32 x 20000 |
| Day's range | 60.50 - 61.35 |
| 52-week range | 59.79 - 80.00 |
| Volume | |
| Avg. volume | 1,059 |
| Market cap | 77.737B |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | 185.36 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.88 (4.81%) |
| Ex-dividend date | 14 Jun 2024 |
| 1y target est | N/A |
- Business Wire
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
FOSTER CITY, Calif. & SANTA MONICA, Calif., May 07, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 18 abstracts during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. These data showcase the ongoing commitment to developing differentiated approaches to transform how cancer is treated and span solid tumors and blood cancers, including lung, breast, gastrointestinal, colorectal, leukemia and lymphoma.
- Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
FOSTER CITY, Calif., April 30, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
- Business Wire
FDA Approves Biktarvy® Label Update With Data for Pregnant Adults With HIV
FOSTER CITY, Calif., April 26, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat pregnant people with HIV-1 (PWH) with suppressed viral loads. These additional data stem from Study 5310, which evaluated the pharmacokinetics, safety and efficacy of
